Blog

    • January 7, 2015

    Vtesse: First Spin-out from Rare Disease Accelerator Cydan

    Today Vtesse, a newly formed biopharma company, announced that it has raised $25 million to develop novel treatments for rare diseases. It’s a significant milestone for several reasons, first and foremost because the funds will enable Vtesse to advance clinical study of VTS-270 for the treatment of a devastating genetic rare disease called Niemann-Pick Disease Type C (NPC). Currently there is no approved treatment for this lysosomal storage disease (LSD) affecting an estimated one in 100,000 to…